Vaxcyte pneumococcal vaccine hits Phase 3 endpoints, stock surges
· Health · United States
Vaxcyte said its experimental pneumococcal vaccine VAX-31 met the primary endpoints in a Phase 3 trial in adults, sending shares up about 35% in Monday trading. The result matched the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials, which Endpoints described as near best-case and BioPharma Dive said surpassed Wall Street expectations. The data set up Vaxcyte to compete in the lucrative pneumococcal vaccine market long dominated by Pfizer and Merck.
Why it matters：A credible new entrant could reshape the pneumococcal vaccine market and pricing pressure on the two dominant suppliers.
Key points
- VAX-31 met primary endpoints in a Phase 3 adult trial.
- Shares rose about 35% on the news.
- It matched Pfizer and Merck shots on nearly all strains tested.
Sources (original reporting)
More stories from this day
- Shionogi to buy rare disease biotech IntraBio for $2B
- Roche pays Alector $100M upfront for Parkinson's drug deal
- FDA approves Lilly's Jaypirca as first-line CLL therapy
- First Solar sues JA Solar, American Panel Solutions over TOPCon patents
- US finalises lower fuel economy standards, ends credit trading
- Supreme Court Weighs Climate Deception Case Against Oil Companies